Rating only — no written review
Orliman x Thetis Medical

An Orliman-branded Achilles night product for Spanish and Portuguese markets.
Thetis has proven the Achilles rupture night splint. Orliman has the orthopaedic brand and regional reach to localise it for Spain, Portugal, and Brazil.
Achilles rupture · Orliman
Orliman can own the Spanish and Portuguese-language recovery offer.
Thetis has the purpose-built Achilles night splint. Orliman has the orthopaedic brand, manufacturing credibility, and regional reach needed to make it feel local in Spain, Portugal, and Brazil.
Orliman
Trusted orthopaedic brand
A recognised Spanish orthopaedic manufacturer with 30+ years in braces, supports, and technical orthopaedic products.
Market reach
Spain, Portugal, Brazil
The markets where Thetis wants help are language-led and relationship-led. Orliman can make the product feel native to clinicians, orthopaedic retailers, and patients.
Thetis
Achilles night splint
A patented ~200 g ATR-specific splint that protects plantarflexion when the walking boot comes off at night, at rest, or during hygiene.
The night problem
Patients struggle at night
In Achilles clinics, the same pattern appears repeatedly: patients are protected in a walking boot by day but struggle to sleep in it at night.
We surveyed Achilles rupture patients. 77% said the boot was:
Online launch
Live sales prove demand
Launched in 2022. Over 5,000 sold. Refined through 400+ prototypes into a left/right top-of-leg shell built for ATR sleep protection.
The Only Splint for Achilles Tendon Rupture
Finally, a comfortable solution for sleep. Designed alongside surgeons to protect your healing Achilles tendon while you get the rest you need.
Choose your Options
Recommended Size:
303 Global Ratings
Showing 5 of 171 reviews from Patients
Relief
Great product to use about five or six weeks into a ruptured Achilles injury instead of the heavy large clumsy dirty boot they pit you in. Keeps the foot in a great healing position and you get a good nights rest.
Excellent service and delivery
Excellent service and delivery. Loved the recovery tips. Love how this company has attention to detail, and looks after you.
gute Alternative zur Orthese
Eine gute und leichte Alternative wenn man die schwere Orthese nicht im Bett tragen möchte. Leider drückt das Teil ziemlich auf den Vorderfuss, dadurch behält man zwangsläufig die richtige Fußstellung ( was wohl so gedacht ist). War sehr zufrieden.
Comfortable and fit great
Perfect for sleeping!! I have a very injured Achilles tendon and this makes sleeping much better. It’s comfortable and fit perfectly. Also stayed in place while sleeping. I felt like my ankle was supported better in this than the boot I have.
Proof
Surgeons say yes
Leading foot and ankle surgeons recommend the splint for night-time use - the problem the walking boot cannot solve.
-
“A game-changer in my practice. The splint's design prioritizes both comfort and functionality, enabling controlled, progressive recovery.”
Dr Robbie Ray
Foot and Ankle Surgeon
-
“When I tore my own Achilles tendon, the hardest part was wearing the hospital boot in bed. This splint is certain to improve the recovery experience for patients.”
Mr James Davis
Past President of the British Orthopaedic Foot and Ankle Society
-
“Makes complete sense to use something like this and I highly recommend this product. Comfort and usability all round.”
Mr Andy Roche
Foot and Ankle Surgeon
-
“Worth every penny as it stops the misery of trying to get good nights sleep in an uncomfortable boot!”
Mr Ian Gill
Foot and Ankle Surgeon
Safety evidence
Clinically proven safety
Over 5,000 splints in use - zero reported re-ruptures. Post-market surveillance confirms night-time injury risk below 0.1% (95% CI).
-
5,000+
Splints sold & tracked
-
0
Reported re-ruptures
-
<0.1%
Night injury risk upper bound (95% CI)
Recovery-period safety assessment recorded comparable protection to a walking boot with substantially better comfort for sleep (Sleeping safe and sound, BOFAS 2024).
EU MDR post-market surveillance (2022–2025) on 5,000+ splints sold shows the same safety profile: zero reported re-ruptures, with a 95% confidence interval upper bound for night-time injury below 0.1%.
- BOFAS 2024 - Sleeping safe and sound
- BOFAS 2023 - Mother Knows Best
- Post-market surveillance - EU MDR vigilance (2022–2025)
IP portfolio
Intellectual property
Thetis Medical owns a growing patent and design portfolio covering the Achilles rupture night splint - relevant for distribution, white-label, and in-region manufacturing under licence. UK and US design protection is in place; US and European utility patents are in late-stage examination.
Portfolio at a glance
UK registered designs
3 registrations — granted 2023
US design patents
3 patents — granted 2025
US utility patent
Application filed 2024 · examination ongoing
European patent (EP)
Pan-European utility application filed 2024 · examination ongoing
Design and utility protection supports distribution, white-label, and in-region manufacturing under licence - without starting from a blank IP slate.
Full portfolio schedule and filing status available to qualified partners under NDA.
Regulatory & quality
Regulatory & quality
Class I device documentation is ready for Orliman review: technical file, EU/UK MDR documentation, post-market surveillance, and launch support. Brazil / ANVISA route to be assessed with Orliman.
Documentation & quality
Technical documentation
Technical file, Declaration of Conformity, IFU, and risk management summary
Post-market surveillance
Vigilance and complaint handling processes in place
Manufacturing
Designed and manufactured in the United Kingdom
EU & UK
UKCA & CE marking
Class I medical device under EU/UK MDR
EUDAMED
Registered in the EU medical devices database
EC-REP
EU Authorised Representative appointed
MHRA
UK manufacturer registered with MHRA
UDI (GS1)
Unique Device Identifier assigned - traceable per unit
Global markets
FDA (United States)
510(k) exempt · establishment 3022381831 · listing D470976
MDEL (Canada)
Health Canada Medical Device Establishment Licence registered
TGA (Australia)
Included on the Australian Register of Therapeutic Goods (ARTG)
Läkemedelsverket (Sweden)
Registered with Sweden's Medical Products Agency
INFARMED (Portugal)
Registered with Portugal's national medicines and health products authority
Full technical file, registration certificates, and market-by-market regulatory pack available to Orliman under NDA.
Partnership context
Why now
Thetis is profitable and growing without outside funding. The next stage is best accelerated by partners that can localise the product into markets where patients and clinicians already ask for better night-time protection.
Steady unit growth
350 -> 2,600 units (2022-2026), before regional manufacturer distribution
90% direct to patient
~90% sold direct to patients today - demand exists before Orliman-led clinical, retail, and wholesale scaling
Unserved regional demand
~65,000 ATR ruptures a year across Spain, Portugal, and Brazil — with almost no Thetis distribution today
Splints sold per year
Growth achieved with ~90% of sales direct to patients, before partner-led regional distribution.
Dotted line = projected volume with Orliman distribution
Why Orliman fits
We are not asking you to change your portfolio. We are asking you to use your reach.
The opportunity is not to replace an existing Orliman product. It is to add a branded Achilles rupture night product into the channels where Orliman already has trust.
~65,000 ATR ruptures a year
Across Spain, Portugal, and Brazil alone — before wider Spanish-speaking Latin America. Thetis reaches almost none of them today.
Planning estimate using ~25-30 ATR ruptures per 100k person-years.
Orliman-branded ATR night splint
Thetis can provide the product, evidence, IP, regulatory file, and launch know-how. Orliman can provide local brand trust, clinician access, orthopaedic retail relationships, and Spanish / Portuguese market execution.
Launch markets
- 🇪🇸
Spain
Home market credibility
~12k ATR ruptures / year
A Spanish Orliman -branded product is easier for surgeons, orthopaedic shops, and patients to trust than an imported English-language DTC product.
- 🇵🇹
Portugal
Neighbouring Iberian reach
2,500 ATR ruptures / year
Portugal is a natural extension for an Iberian orthopaedic partner: close geography, aligned product education, and a similar clinic-retail pathway.
- 🇧🇷
Brazil
Portuguese-language scale
~50k ATR ruptures / year
Brazil is the largest upside market in the ask. Thetis needs a partner that can translate evidence and demand into local orthopaedic access.
The ask
Partnership with Orliman
We want Orliman to take our proven Achilles rupture night splint and sell it as an Orliman-branded product in Spain, Portugal, and Brazil — using the channels and trust you already have.
Sell the Thetis splint under the Orliman brand
Why it is commercially simple
Patient RRP
~€79.99 target EU patient price
Simple range
4 SKUs: small / large, left / right
Add-on sale
A lightweight orthopaedic retail and clinician-recommendation product, not a boot replacement
What we need from Orliman
- Sell an Orliman-branded ATR night splint in Spain, Portugal, and Brazil
- Own the local positioning: Orliman packaging, clinician education, orthopaedic retail, and distributor activation
What Thetis provides
- Product know-how, clinical evidence, IP access, regulatory documentation, launch support, and Spanish instructions already prepared
- Spanish / Portuguese launch assets adapted to Orliman's preferred local wording and brand style
Low-risk pilot
- Start with Spain and Portugal for 6 months, then review Brazil expansion
- Agree an opening order, Orliman-branded materials, and a simple clinician education pack
- Review orders, clinician feedback, and retail pull-through before scaling